Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.
Identifieur interne : 001F37 ( PubMed/Curation ); précédent : 001F36; suivant : 001F38Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.
Auteurs : Leon Poltawski [Royaume-Uni] ; Hazel Edwards ; Amy Todd ; Tim Watson ; Andrew Lees ; Cherry Ann JamesSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Apomorphine (adverse effects), Apomorphine (therapeutic use), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Drug Eruptions (etiology), Drug Eruptions (therapy), Female, Hardness, Humans, Infusions, Parenteral (adverse effects), Male, Middle Aged, Parkinson Disease (drug therapy), Pilot Projects, Sample Size, Subcutaneous Tissue (pathology), Ultrasonic Therapy.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Apomorphine, Dopamine Agonists.
- chemical , therapeutic use : Antiparkinson Agents, Apomorphine, Dopamine Agonists.
- adverse effects : Infusions, Parenteral.
- drug therapy : Parkinson Disease.
- etiology : Drug Eruptions.
- pathology : Subcutaneous Tissue.
- therapy : Drug Eruptions.
- Aged, Female, Hardness, Humans, Male, Middle Aged, Pilot Projects, Sample Size, Ultrasonic Therapy.
Abstract
Apomorphine hydrochloride is a dopamine agonist used in the treatment of advanced Parkinson's disease. Its administration by subcutaneous infusions is associated with the development of nodules that may interfere with absorption of the drug. This pilot study assessed the effectiveness of ultrasound (US) in the treatment of these nodules. Twelve participants were randomly assigned to receive a course of real or sham US on an area judged unsuitable for infusion. Following treatment, no significant change was observed in measures of tissue hardness and tenderness. However, 5 of 6 participants receiving real US rated the treated area suitable for infusion compared with the 1 of 6 receiving sham US. Sonographic appearance improved in both groups, but more substantially in the real US group. Power calculations suggest a total sample size of 30 would be required to establish statistical significance. A full-scale study of the effectiveness of therapeutic US in the treatment of apomorphine nodules is warranted.
DOI: 10.1002/mds.22316
PubMed: 19006068
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001F37
Links to Exploration step
pubmed:19006068Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.</title><author><name sortKey="Poltawski, Leon" sort="Poltawski, Leon" uniqKey="Poltawski L" first="Leon" last="Poltawski">Leon Poltawski</name><affiliation wicri:level="1"><nlm:affiliation>Division of Physiotherapy, University of Hertfordshire, UK. l.poltawski@herts.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Physiotherapy, University of Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Edwards, Hazel" sort="Edwards, Hazel" uniqKey="Edwards H" first="Hazel" last="Edwards">Hazel Edwards</name></author><author><name sortKey="Todd, Amy" sort="Todd, Amy" uniqKey="Todd A" first="Amy" last="Todd">Amy Todd</name></author><author><name sortKey="Watson, Tim" sort="Watson, Tim" uniqKey="Watson T" first="Tim" last="Watson">Tim Watson</name></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name></author><author><name sortKey="James, Cherry Ann" sort="James, Cherry Ann" uniqKey="James C" first="Cherry Ann" last="James">Cherry Ann James</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22316</idno><idno type="RBID">pubmed:19006068</idno><idno type="pmid">19006068</idno><idno type="wicri:Area/PubMed/Corpus">001F37</idno><idno type="wicri:Area/PubMed/Curation">001F37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.</title><author><name sortKey="Poltawski, Leon" sort="Poltawski, Leon" uniqKey="Poltawski L" first="Leon" last="Poltawski">Leon Poltawski</name><affiliation wicri:level="1"><nlm:affiliation>Division of Physiotherapy, University of Hertfordshire, UK. l.poltawski@herts.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Physiotherapy, University of Hertfordshire</wicri:regionArea></affiliation></author><author><name sortKey="Edwards, Hazel" sort="Edwards, Hazel" uniqKey="Edwards H" first="Hazel" last="Edwards">Hazel Edwards</name></author><author><name sortKey="Todd, Amy" sort="Todd, Amy" uniqKey="Todd A" first="Amy" last="Todd">Amy Todd</name></author><author><name sortKey="Watson, Tim" sort="Watson, Tim" uniqKey="Watson T" first="Tim" last="Watson">Tim Watson</name></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name></author><author><name sortKey="James, Cherry Ann" sort="James, Cherry Ann" uniqKey="James C" first="Cherry Ann" last="James">Cherry Ann James</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Apomorphine (adverse effects)</term><term>Apomorphine (therapeutic use)</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Eruptions (etiology)</term><term>Drug Eruptions (therapy)</term><term>Female</term><term>Hardness</term><term>Humans</term><term>Infusions, Parenteral (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Pilot Projects</term><term>Sample Size</term><term>Subcutaneous Tissue (pathology)</term><term>Ultrasonic Therapy</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Apomorphine</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Infusions, Parenteral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Drug Eruptions</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Subcutaneous Tissue</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Drug Eruptions</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Hardness</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term><term>Sample Size</term><term>Ultrasonic Therapy</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Apomorphine hydrochloride is a dopamine agonist used in the treatment of advanced Parkinson's disease. Its administration by subcutaneous infusions is associated with the development of nodules that may interfere with absorption of the drug. This pilot study assessed the effectiveness of ultrasound (US) in the treatment of these nodules. Twelve participants were randomly assigned to receive a course of real or sham US on an area judged unsuitable for infusion. Following treatment, no significant change was observed in measures of tissue hardness and tenderness. However, 5 of 6 participants receiving real US rated the treated area suitable for infusion compared with the 1 of 6 receiving sham US. Sonographic appearance improved in both groups, but more substantially in the real US group. Power calculations suggest a total sample size of 30 would be required to establish statistical significance. A full-scale study of the effectiveness of therapeutic US in the treatment of apomorphine nodules is warranted.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19006068</PMID><DateCreated><Year>2009</Year><Month>02</Month><Day>02</Day></DateCreated><DateCompleted><Year>2009</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.</ArticleTitle><Pagination><MedlinePgn>115-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22316</ELocationID><Abstract><AbstractText>Apomorphine hydrochloride is a dopamine agonist used in the treatment of advanced Parkinson's disease. Its administration by subcutaneous infusions is associated with the development of nodules that may interfere with absorption of the drug. This pilot study assessed the effectiveness of ultrasound (US) in the treatment of these nodules. Twelve participants were randomly assigned to receive a course of real or sham US on an area judged unsuitable for infusion. Following treatment, no significant change was observed in measures of tissue hardness and tenderness. However, 5 of 6 participants receiving real US rated the treated area suitable for infusion compared with the 1 of 6 receiving sham US. Sonographic appearance improved in both groups, but more substantially in the real US group. Power calculations suggest a total sample size of 30 would be required to establish statistical significance. A full-scale study of the effectiveness of therapeutic US in the treatment of apomorphine nodules is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poltawski</LastName><ForeName>Leon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Physiotherapy, University of Hertfordshire, UK. l.poltawski@herts.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Hazel</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lees</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Cherry Ann</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K-0615</GrantID><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001058">Apomorphine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003875">Drug Eruptions</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006244">Hardness</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007263">Infusions, Parenteral</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018401">Sample Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D040521">Subcutaneous Tissue</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D014464">Ultrasonic Therapy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22316</ArticleId><ArticleId IdType="pubmed">19006068</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001F37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:19006068
|texte= Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:19006068" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |